Archive for July 2017

$280 Million Celgene Settlement Cites Cancer Drug Promotion


Pharmaceutical giant Celgene has been accused of “fast and loose” marketing practices that cynically targeted vulnerable cancer patients. Following news that the company agreed to pay a $280 million settlement related to Thalomid and Revlimid, prosecutors pointed to the dangerous ways in which Celgene cut corners just to sell more of its cancer drugs. The substantial…

Read More

Blood Thinners Associated with 3,000 Deaths in 2016


More than one million “adverse events” related to drugs were reported to the FDA in 2016. Among this overwhelming number, around 22,000 complaints concerned oral anticoagulants drugs like Xarelto, Eliquis, and other familiar brand names.  Even more concerning is the fact that this class of drug, more commonly known as blood thinners, were associated with…

Read More

Mistrial Threatens Chances of Talcum Powder Plaintiffs

mistrial for talcum powder plaintiffs

The outcome of nationwide talcum powder litigation has been blown wide open by a Missouri judge’s decision to declare a mistrial.  St. Louis Circuit Judge Rex Burlison announced his ruling late last month after Johnson & Johnson filed a request to reconsider the case. His decision threatens talcum powder plaintiffs past and present. The decision…

Read More

IVC Filter Retrieval: A Longer Dwell Time Means More Risk


Inferior vena cava (IVC) filters have been classed as a potentially hazardous medical device since 2014 when the FDA recommended removing the filter as soon as the minimum required protection period had passed. Now a new study has quantified the risk of delaying IVC filter retrieval.  The news is not good for anyone who has…

Read More